TD Cowen Sticks to Its Hold Rating for Standard BioTools (LAB)

TD Cowen analyst Daniel Brennan maintained a Hold rating on Standard BioTools on October 10 and set a price target of $1.55. The company’s shares closed yesterday at $1.29.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Brennan is a 5-star analyst with an average return of 18.4% and a 56.25% success rate. Brennan covers the Healthcare sector, focusing on stocks such as Bruker, Guardant Health, and Avantor.

Currently, the analyst consensus on Standard BioTools is a Hold with an average price target of $1.53, implying a 18.60% upside from current levels. In a report released on October 11, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $1.50 price target.

Based on Standard BioTools’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $21.76 million and a GAAP net loss of $33.46 million. In comparison, last year the company earned a revenue of $37.21 million and had a GAAP net loss of $45.72 million

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LAB in relation to earlier this year. Last month, Casdin Partners Master Fund, L.P., a Director at LAB bought 100,000.00 shares for a total of $128,000.00.